Vigabatrin
| Clinical data | |
|---|---|
| Pronunciation | /vaɪˈɡæbətrɪn/ vy-GAB-ə-trin |
| Trade names | Vigafyde, Sabril, others |
| Other names | γ-Vinyl-GABA |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610016 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80–90% |
| Protein binding | 0% |
| Metabolism | not metabolized |
| Elimination half-life | 5–8 hours in young adults, 12–13 hours in the elderly. |
| Excretion | Kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.165.122 |
| Chemical and physical data | |
| Formula | C6H11NO2 |
| Molar mass | 129.159 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 171 to 177 °C (340 to 351 °F) |
| |
| |
| (verify) | |
Vigabatrin, sold under the brand name Vigafyde among others, is a medication used in the management and treatment of infantile spasms and refractory complex partial seizures.
It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.
Vigabatrin is generally used only in cases of treatment-resistant epilepsy due to the risk of permanent vision loss. Although estimates of visual field loss vary substantially, risk appears to be lower among infants with treatment duration less than 12 months and the risk of clinically meaningful vision loss is very low among children treated for infantile spasms.